The Global Asthma Therapeutics Market is anticipated to grow at a CAGR of 5.2% during the forecast period and reach USD 22.4 billion by 2028. Asthma is a lung disorder wherein inflammation causes the bronchi to swell and narrow down the airways resulting in breathing difficulties that may be a mild or life-threatening inconsiderable number of cases.

Key Developments in Asthma Therapeutics Market:
• In November 2017, U.S. Food and Drug Administration (USFDA) announced the approval of Fasenra (benralizumab). It is used for the treatment and management of severe asthma inpatient. Fasenra is a new precision biologic, intended to improve the condition of severe asthma patients.
• In February 2018, Teva Pharmaceutical Industries Ltd. launched its new QVAR RediHaler (Beclomethasone Dipropionate HFA) Inhalation Aerosol in the U.S. It is used for the treatment and control of asthma. This breath-actuated aerosol contains corticosteroid for the maintenance and treatment of asthma as prophylactic therapy in patients.